
Rick L Tarleton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6983837/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Strain-specific genome evolution in Trypanosoma cruzi, the agent of Chagas disease. PLoS Pathogens, 2021, 17, e1009254.	4.7	50
2	High variation in immune responses and parasite phenotypes in naturally acquired Trypanosoma cruzi infection in a captive non-human primate breeding colony in Texas, USA. PLoS Neglected Tropical Diseases, 2021, 15, e0009141.	3.0	12
3	Reduced <i>Trypanosoma cruzi</i> -specific humoral response and enhanced T cell immunity after treatment interruption with benznidazole in chronic Chagas disease. Journal of Antimicrobial Chemotherapy, 2021, 76, 1580-1592.	3.0	5
4	A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease. Science Translational Medicine, 2020, 12, .	12.4	31
5	Cutting Edge: Augmenting Muscle MHC Expression Enhances Systemic Pathogen Control at the Expense of T Cell Exhaustion. Journal of Immunology, 2020, 205, 573-578.	0.8	5
6	New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
7	Protozoan persister-like cells and drug treatment failure. Nature Reviews Microbiology, 2019, 17, 607-620.	28.6	97
8	Chagas Disease Drug Discovery: Multiparametric Lead Optimization against <i>Trypanosoma cruzi</i> in Acylaminobenzothiazole Series. Journal of Medicinal Chemistry, 2019, 62, 10362-10375.	6.4	11
9	Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, 2019, 5, 152-157.	3.8	78
10	Highly competent, non-exhausted CD8+ T cells continue to tightly control pathogen load throughout chronic Trypanosoma cruzi infection. PLoS Pathogens, 2018, 14, e1007410.	4.7	36
11	Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes. Frontiers in Immunology, 2018, 9, 1958.	4.8	22
12	Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. ELife, 2018, 7, .	6.0	169
13	Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection. Npj Vaccines, 2017, 2, 9.	6.0	45
14	Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins. MBio, 2017, 8, .	4.1	88
15	The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to Trypanosoma cruzi in Serodiscordant Subjects. Frontiers in Immunology, 2017, 8, 1141.	4.8	11
16	Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant <i>trans</i> -Sialidase-Specific CD8 ⁺ T Cells. Infection and Immunity, 2016, 84, 2627-2638.	2.2	12
17	Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi. BMC Genomics, 2016, 17, 729.	2.8	31
18	Chagas Disease: A Solvable Problem, Ignored. Trends in Molecular Medicine, 2016, 22, 835-838.	6.7	21

#	Article	IF	CITATIONS
19	Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses. PLoS Neglected Tropical Diseases, 2016, 10, e0004657.	3.0	32
20	Immunity to Trypanosoma cruzi. , 2016, , 108-113.		1
21	Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 445-451.	1.6	33
22	CRISPR-Cas9-Mediated Single-Gene and Gene Family Disruption in Trypanosoma cruzi. MBio, 2015, 6, e02097-14.	4.1	186
23	CD8+ T cells in Trypanosoma cruzi infection. Seminars in Immunopathology, 2015, 37, 233-238.	6.1	109
24	Perturbed T Cell IL-7 Receptor Signaling in Chronic Chagas Disease. Journal of Immunology, 2015, 194, 3883-3889.	0.8	24
25	Chemokine receptor 7 (CCR7)-expression and IFNÎ ³ production define vaccine-specific canine T-cell subsets. Veterinary Immunology and Immunopathology, 2015, 164, 127-136.	1.2	15
26	A framework for ontology-based question answering with application to parasite immunology. Journal of Biomedical Semantics, 2015, 6, 31.	1.6	23
27	EuPaGDT: a web tool tailored to design CRISPR guide RNAs for eukaryotic pathogens. Microbial Genomics, 2015, 1, e000033.	2.0	174
28	Chagas Disease and the London Declaration on Neglected Tropical Diseases. PLoS Neglected Tropical Diseases, 2014, 8, e3219.	3.0	61
29	Frequency of IFNγ-producing T cells correlates with seroreactivity and activated T cells during canine Trypanosoma cruzi infection. Veterinary Research, 2014, 45, 6.	3.0	13
30	New, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice. Journal of Infectious Diseases, 2014, 209, 150-162.	4.0	118
31	The Trypanosoma cruzi Flagellum Is Discarded via Asymmetric Cell Division following Invasion and Provides Early Targets for Protective CD8+ T Cells. Cell Host and Microbe, 2014, 16, 439-449.	11.0	44
32	Potential new clinical therapies for Chagas disease. Expert Review of Clinical Pharmacology, 2014, 7, 317-325.	3.1	35
33	Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in <i><scp>T</scp>rypanosoma cruzi</i> persistence. Molecular Microbiology, 2013, 90, 699-715.	2.5	31
34	Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nature Communications, 2013, 4, 2616.	12.8	38
35	Polyfunctional T Cell Responses in Children in Early Stages of Chronic Trypanosoma cruzi Infection Contrast with Monofunctional Responses of Long-term Infected Adults. PLoS Neglected Tropical Diseases, 2013, 7, e2575.	3.0	45
36	Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. Journal of Antimicrobial Chemotherapy, 2013, 68, 424-437.	3.0	46

#	Article	IF	CITATIONS
37	A Systematic Review of High Quality Diagnostic Tests for Chagas Disease. PLoS Neglected Tropical Diseases, 2012, 6, e1881.	3.0	78
38	A Semantic Problem Solving Environment for Integrative Parasite Research: Identification of Intervention Targets for Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2012, 6, e1458.	3.0	5
39	Is Chagas Disease Really the "New HIV/AIDS of the Americas�. PLoS Neglected Tropical Diseases, 2012, 6, e1861.	3.0	26
40	Transgenic parasites accelerate drug discovery. Trends in Parasitology, 2012, 28, 90-92.	3.3	13
41	Inhibitory Receptors Are Expressed by Trypanosoma cruzi-Specific Effector T Cells and in Hearts of Subjects with Chronic Chagas Disease. PLoS ONE, 2012, 7, e35966.	2.5	58
42	Methodological advances in drug discovery for Chagas disease. Expert Opinion on Drug Discovery, 2011, 6, 653-661.	5.0	31
43	Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA. Expert Opinion on Drug Discovery, 2011, 6, 965-973.	5.0	9
44	Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics, 2011, 12, 139.	2.8	80
45	Oral Exposure to Trypanosoma cruzi Elicits a Systemic CD8 ⁺ T Cell Response and Protection against Heterotopic Challenge. Infection and Immunity, 2011, 79, 3397-3406.	2.2	33
46	Epigenetic Regulation of Transcription and Virulence in Trypanosoma cruzi by O-Linked Thymine Glucosylation of DNA. Molecular and Cellular Biology, 2011, 31, 1690-1700.	2.3	40
47	Impact of Aetiological Treatment on Conventional and Multiplex Serology in Chronic Chagas Disease. PLoS Neglected Tropical Diseases, 2011, 5, e1314.	3.0	93
48	Knockout of the dhfr-ts Gene in Trypanosoma cruzi Generates Attenuated Parasites Able to Confer Protection against a Virulent Challenge. PLoS Neglected Tropical Diseases, 2011, 5, e1418.	3.0	20
49	Identification of Contractile Vacuole Proteins in Trypanosoma cruzi. PLoS ONE, 2011, 6, e18013.	2.5	69
50	Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes and Infection, 2010, 12, 359-363.	1.9	16
51	Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorganic and Medicinal Chemistry, 2010, 18, 2880-2886.	3.0	36
52	Generation of <i>Trypanosoma cruzi</i> -Specific CD8 ⁺ T-Cell Immunity Is Unaffected by the Absence of Type I Interferon Signaling. Infection and Immunity, 2010, 78, 3154-3159.	2.2	15
53	In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi Compounds. PLoS Neglected Tropical Diseases, 2010, 4, e740.	3.0	140
54	CD8+ T Cells Specific for Immunodominant <i>Trans</i> -Sialidase Epitopes Contribute to Control of <i>Trypanosoma cruzi</i> Infection but Are Not Required for Resistance. Journal of Immunology, 2010, 185, 560-568.	0.8	58

#	Article	IF	CITATIONS
55	Chronic Human Infection with <i>Trypanosoma cruzi</i> Drives CD4+ T Cells to Immune Senescence. Journal of Immunology, 2009, 183, 4103-4108.	0.8	103
56	Changes in <i>Trypanosoma cruzi</i> –Specific Immune Responses after Treatment: Surrogate Markers of Treatment Efficacy. Clinical Infectious Diseases, 2009, 49, 1675-1684.	5.8	98
57	Insufficient TLR Activation Contributes to the Slow Development of CD8+ T Cell Responses in <i>Trypanosoma cruzi</i> Infection. Journal of Immunology, 2009, 183, 1245-1252.	0.8	76
58	Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genomics, 2009, 10, 255.	2.8	108
59	The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics, 2009, 10, 370.	2.8	125
60	Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiology, 2009, 9, 90.	3.3	35
61	CD8+ T cells in Trypanosoma cruzi infection. Current Opinion in Immunology, 2009, 21, 385-390.	5.5	137
62	Proteomic analysis of the Trypanosoma cruzi ribosomal proteins. Biochemical and Biophysical Research Communications, 2009, 382, 30-34.	2.1	20
63	Ontology-Driven Provenance Management in eScience: An Application in Parasite Research. Lecture Notes in Computer Science, 2009, , 992-1009.	1.3	9
64	Eliminating Chagas disease: challenges and a roadmap. BMJ: British Medical Journal, 2009, 338, b1283-b1283.	2.3	52
65	Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nature Medicine, 2008, 14, 542-550.	30.7	186
66	Stable CD8+ T Cell Memory during Persistent <i>Trypanosoma cruzi</i> Infection. Journal of Immunology, 2008, 181, 2644-2650.	0.8	57
67	Kinetoplastids: related protozoan pathogens, different diseases. Journal of Clinical Investigation, 2008, 118, 1301-1310.	8.2	460
68	High Throughput Selection of Effective Serodiagnostics for Trypanosoma cruzi infection. PLoS Neglected Tropical Diseases, 2008, 2, e316.	3.0	93
69	HLA Class I-T Cell Epitopes from trans-Sialidase Proteins Reveal Functionally Distinct Subsets of CD8+ T Cells in Chronic Chagas Disease. PLoS Neglected Tropical Diseases, 2008, 2, e288.	3.0	66
70	Endogenous CD4 ⁺ CD25 ⁺ Regulatory T Cells Have a Limited Role in the Control of <i>Trypanosoma cruzi</i> Infection in Mice. Infection and Immunity, 2007, 75, 861-869.	2.2	79
71	The Challenges of Chagas Disease— Grim Outlook or Glimmer of Hope?. PLoS Medicine, 2007, 4, e332.	8.4	196
72	Limited Role for CD4 + T-Cell Help in the Initial Priming of Trypanosoma cruzi- Specific CD8 + T Cells. Infection and Immunity, 2007, 75, 231-235.	2.2	39

#	Article	IF	CITATIONS
73	A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biology, 2007, 8, R110.	9.6	23
74	TGFâ€Î² regulates pathology but not tissue CD8 ⁺ T cell dysfunction during experimental <i>Trypanosoma cruzi</i> infection. European Journal of Immunology, 2007, 37, 2764-2771.	2.9	48
75	Multidimensional analysis of the insoluble sub-proteome ofOceanobacillus iheyensis HTE831, an alkaliphilic and halotolerant deep-sea bacterium isolated from the Iheya ridge. Proteomics, 2007, 7, 82-91.	2.2	23
76	Immune system recognition of Trypanosoma cruzi. Current Opinion in Immunology, 2007, 19, 430-434.	5.5	184
77	A Combined Shotgun and Multidimensional Proteomic Analysis of the Insoluble Subproteome of the Obligate Thermophile,GeobacillusthermoleovoransT80. Journal of Proteome Research, 2006, 5, 2465-2473.	3.7	13
78	Glycoproteomics ofTrypanosoma cruziTrypomastigotes Using Subcellular Fractionation, Lectin Affinity, and Stable Isotope Labeling. Journal of Proteome Research, 2006, 5, 3376-3384.	3.7	84
79	Multidimensional Proteomic Analysis of the Soluble Subproteome of the Emerging Nosocomial PathogenOchrobactrumanthropi. Journal of Proteome Research, 2006, 5, 3145-3153.	3.7	13
80	Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. International Immunology, 2006, 18, 465-471.	4.0	134
81	CD8+ T-Cell Responses to Trypanosoma cruzi Are Highly Focused on Strain-Variant trans-Sialidase Epitopes. PLoS Pathogens, 2006, 2, e77.	4.7	204
82	Analysis of theTrypanosoma cruzicyclophilin gene family and identification of Cyclosporin A binding proteins. Parasitology, 2006, 132, 867-882.	1.5	21
83	Antigen-Specific T Cells Maintain an Effector Memory Phenotype during Persistent <i>Trypanosoma cruzi</i> Infection. Journal of Immunology, 2005, 174, 1594-1601.	0.8	76
84	New approaches in vaccine development for parasitic infections. Cellular Microbiology, 2005, 7, 1379-1386.	2.1	21
85	A Heuristic Method for Assigning a False-discovery Rate for Protein Identifications from Mascot Database Search Results. Molecular and Cellular Proteomics, 2005, 4, 762-772.	3.8	180
86	The Genome Sequence of <i>Trypanosoma cruzi</i> , Etiologic Agent of Chagas Disease. Science, 2005, 309, 409-415.	12.6	1,273
87	The Trypanosoma cruzi Proteome. Science, 2005, 309, 473-476.	12.6	383
88	Inducible Nitric Oxide Synthase Is Not Essential for Control of <i>Trypanosoma cruzi</i> Infection in Mice. Infection and Immunity, 2004, 72, 4081-4089.	2.2	58
89	TcruziDB: an integrated Trypanosoma cruzi genome resource. Nucleic Acids Research, 2004, 32, 344D-346.	14.5	12
90	Frequency of Interferonâ€Î³â€"Producing T Cells Specific forTrypanosoma cruziInversely Correlates with Disease Severity in Chronic Human Chagas Disease. Journal of Infectious Diseases, 2004, 189, 909-918.	4.0	180

#	Article	IF	CITATIONS
91	Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection. Immunological Reviews, 2004, 201, 304-317.	6.0	134
92	Chagas disease: a role for autoimmunity?. Trends in Parasitology, 2003, 19, 447-451.	3.3	138
93	Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Molecular and Biochemical Parasitology, 2003, 129, 53-59.	1.1	227
94	Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi. Molecular and Biochemical Parasitology, 2003, 131, 55-64.	1.1	42
95	Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine, 2003, 21, 3070-3080.	3.8	60
96	Cutting Edge: Dysfunctional CD8+ T Cells Reside in Nonlymphoid Tissues During Chronic <i>Trypanosoma cruzi</i> Infection. Journal of Immunology, 2003, 170, 2264-2268.	0.8	53
97	Genetic Immunization Elicits Antigen-Specific Protective Immune Responses and Decreases Disease Severity in Trypanosoma cruzi Infection. Infection and Immunity, 2002, 70, 5547-5555.	2.2	118
98	Parasite genomics: current status and future prospects. Current Opinion in Immunology, 2001, 13, 395-402.	5.5	25
99	Parasite persistence in the aetiology of Chagas disease. International Journal for Parasitology, 2001, 31, 550-554.	3.1	254
100	Antigen-Specific Th1 But Not Th2 Cells Provide Protection from Lethal <i>Trypanosoma cruzi</i> Infection in Mice. Journal of Immunology, 2001, 166, 4596-4603.	0.8	103
101	Increased Susceptibility of Stat4-Deficient and Enhanced Resistance in Stat6-Deficient Mice to Infection withTrypanosoma cruzi. Journal of Immunology, 2000, 165, 1520-1525.	0.8	103
102	A new liquid chromatography/tandem mass spectrometric approach for the identification of class I major histocompatibility complex associated peptides that eliminates the need for bioassays. , 1999, 13, 1024-1030.		15
103	The relative contribution of antibody production and CD8 ⁺ T cell function to immune control of <i>Trypanosoma cruzi</i> . Parasite Immunology, 1998, 20, 207-216.	1.5	133
104	Vaccination with Trypomastigote Surface Antigen 1-Encoding Plasmid DNA Confers Protection against Lethal <i>Trypanosoma cruzi</i> Infection. Infection and Immunity, 1998, 66, 5073-5081.	2.2	79
105	Proteins with Glycosylphosphatidylinositol (GPI) Signal Sequences Have Divergent Fates during a GPI Deficiency. Journal of Biological Chemistry, 1997, 272, 12482-12491.	3.4	32
106	The identification and molecular characterization of Trypanosoma cruzi amastigote surface protein-1, a member of the trans-sialidase gene super-family1Note: Nucleotide sequence data reported in this paper is available in the GenBank data base under the Accession no. U74494.1. Molecular and Biochemical Parasitology, 1997, 86, 1-11.	1.1	29
107	Molecular cloning of the gene encoding the 83 kDa amastigote surface protein and its identification as a member of the Trypanosoma cruzi sialidase superfamily1Note: Nucleotide sequence data reported in this paper is available in the GenBankâ,,¢ database under the accession number U77951.1. Molecular and Biochemical Parasitology, 1997, 88, 137-149.	1.1	39
108	Persistent Production of Inflammatory and Anti-inflammatory Cytokines and Associated MHC and Adhesion Molecule Expression at the Site of Infection and Disease in ExperimentalTrypanosoma cruziInfections. Experimental Parasitology, 1996, 84, 203-213.	1.2	59

#	Article	IF	CITATIONS
109	Characterization of cytokine production in murineTrypanosoma cruzi infection byin situ immunocytochemistry: Lack of association between susceptibility and type 2 cytokine production. European Journal of Immunology, 1996, 26, 102-109.	2.9	97
110	Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease. International Immunology, 1996, 8, 13-22.	4.0	159
111	Construction and use of a multi-competitor gene for quantitative RT-PCR using existing primer sets. Journal of Immunological Methods, 1995, 181, 145-156.	1.4	39
112	Trypanosoma cruzi infection suppresses nuclear factors that bind to specific sites on the interleukin. European Journal of Immunology, 1994, 24, 16-23.	2.9	23
113	Interleukin 1 activity in haemolymph from strains of the snail biomphalaria glabrata varying in susceptibility to the human blood fluke, Schistosoma mansoni: presence, differential expression, and biological function. Cytokine, 1994, 6, 21-27.	3.2	56
114	In vitro Culture of Cardiac Mast Cells from Mice Experimentally Infected with <i>Trypanosoma cruzi</i> . International Archives of Allergy and Immunology, 1994, 105, 251-257.	2.1	13
115	Differentiation of trypanosomatid species by hybridization to selected rRNA probes. Molecular and Cellular Probes, 1993, 7, 89-96.	2.1	5
116	Predominance of CD8+ T Lymphocytes in the Inflammatory Lesions of Mice with Acute Trypanosoma cruzi Infection. American Journal of Tropical Medicine and Hygiene, 1993, 48, 161-169.	1.4	72
117	Trypanosomes and Microfilariae in Feral Owl and Squirrel Monkeys Maintained in Research Colonies. American Journal of Tropical Medicine and Hygiene, 1993, 49, 254-259.	1.4	17
118	Regulation of immunity in Trypanosoma cruzi infection. Experimental Parasitology, 1991, 73, 106-109.	1.2	30
119	Trypanosoma cruzi: Cytokine effects on macrophage trypanocidal activity. Experimental Parasitology, 1991, 72, 391-402.	1.2	69
120	Fundamental Immunology. American Journal of Tropical Medicine and Hygiene, 1991, 44, 354-354.	1.4	0
121	Interleukin 2 production in patients with Chagas' disease: correlation with anti-parasite antibody responses. Immunology Letters, 1988, 17, 229-234.	2.5	3
122	A Monoclonal Antibody to Alpha Tubulin Recognizes Host Cell andTrypanosoma cruziTubulins1. Journal of Protozoology, 1988, 35, 123-129.	0.8	14
123	Initial induction of immunity, followed by suppression of responses to parasite antigens during Trypanosoma cruzi infection of mice. Parasite Immunology, 1987, 9, 579-589.	1.5	13
124	Biology of tegument associated IgG-Fc and C3 receptors inSchistosoma mansoni. Journal of Chemical Ecology, 1986, 12, 1833-1841.	1.8	6
125	Measurement of parasite-specific immune responsesin vitro: evidence for suppression of the antibody response toTrypanosoma cruzi. European Journal of Immunology, 1985, 15, 845-850.	2.9	28
126	Loss of Suppressor Activity in the Serum of Mice Infected with Trypanosoma cruzi. Journal of Parasitology, 1984, 70, 253.	0.7	3

#	Article	IF	CITATIONS
127	Diagnosis of Chagas' Disease in Humans Using a Biotin-3H-Avidin Radioimmunoassay *. American Journal of Tropical Medicine and Hygiene, 1984, 33, 34-40.	1.4	8
128	Changes in cell populations and immunoglobulin-producing cells in the spleens of mice infected with Trypanosoma cruzi: Correlations with parasite-specific antibody response. Cellular Immunology, 1983, 80, 392-404.	3.0	41
129	Measurement of parasite-specific antibody responses using a tritiated avidin-solid phase radioimmunoassay. Journal of Immunological Methods, 1983, 60, 213-220.	1.4	9
130	Trypanosoma cruzi: Effect on B-cell-responsive and -responding clones. Experimental Parasitology, 1981, 51, 257-268.	1.2	22
131	Overview of Parasitic Pathogens. , 0, , 143-153.		1
132	Overview of the Parasitic Pathogens. , 0, , 39-52.		6